Turkish scientists show promising results with new fertility treatments
Turkish scientists have combined two distinct egg rejuvenation treatments, resulting in pregnancies in 38 out of 100 women.
This innovative approach offers hope to women facing early menopause, even as young as 20s, by potentially restoring their ability to conceive.
The research, led by professor Dr. Bulent Tiras and his team, involved 150 women with diminished or exhausted egg reserves. They applied PRP (Platelet-Rich Plasma) and exosome treatments simultaneously.
The success rate of 38% achieved through this combination marks a world-first clinical trial. These findings will be presented at the prestigious ASRM Congress in the United States, solidifying its impact on medical literature.
‘Science behind success’
Professor Dr. Tiras, at the 21st National Gynecology and Obstetrics Congress, emphasized the revolutionary role of exosomes in regenerative medicine.
He explained exosomes are cellular vesicles rich in growth factors, RNA, and DNA fragments, facilitating cellular communication and repair. This makes them highly effective in skin rejuvenation and wound healing, and now, in fertility treatments.
The study divided women into three groups: one received only PRP, another only exosomes, and the third both treatments. The highest success rate, 38%, was observed in the combined treatment group, compared to 26% for PRP alone and 20% for exosomes alone. Professor Dr. Tiras highlighted this as a significant achievement for women who previously had no hope of conceiving.
Future implications, safety concerns
Menopause typically occurs around 43-44 years of age in Türkiye, but it is becoming more common for women to experience it in their 20s.
This study offers a promising future, potentially extending the age at which women can conceive naturally to 50.
However, Professor Dr. Tiras cautioned about the sources of exosomes used in treatments. He stressed the importance of using exosomes derived from the patient’s blood or urine to avoid the risks associated with foreign DNA.
Exosomes from uncertain sources, particularly those imported from countries like South Korea, may carry unknown diseases and pose serious health risks.
Innovations and regulatory needs
Professor Dr. Ercument Ovali, commenting on the use of imported exosomes, pointed out the legal and safety issues. Exosomes from foreign sources often lack standardization and quality, potentially transferring harmful elements.
In response, his team has developed a new product, PI X, which aims to eliminate these risks by ensuring consistent quality and safety. This product is set to enter clinical trials soon.
The advancements by Turkish scientists in using exosomes and PRP together represent a significant leap forward in fertility treatments, providing new hope for women experiencing early menopause.
With continued research and regulatory oversight, these treatments could become a safe and standard option for those looking to extend their fertility window.
